An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer
Latest Information Update: 26 May 2022
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Anthracyclines; Taxanes
- Indications Early breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms BEATRICE
- Sponsors Roche
- 13 Apr 2022 Samples from this study used to analyze prognostic value of longitudinal ctDNA monitoring in eTNBC patients post-surgery and after adjuvant chemotherapy (ACT) using a custom bespoke ctDNA assay presented at the 113th Annual Meeting of the American Association for Cancer Research
- 11 Apr 2022 Results published in the Natera Media Release
- 11 Apr 2022 According to a Natera media release, company will present new data relating to its personalized and tumor informed molecular residual disease (MRD) test, Signatera, at the annual meeting of the American Association for Cancer Research taking place April 8 -13, 2022.